TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05980949: Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 1000 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$661,152

Rescue Site Savings

+$440,768

Unlock Full NCT05980949 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05980949 Rescue Dossier →